HHLA2 as an emerging immune checkpoint in lung cancer: linking EGFR signaling, macrophage polarization, and CD8+ T-cell metabolic suppression - Takeaways - MDSpire

HHLA2 as an emerging immune checkpoint in lung cancer: linking EGFR signaling, macrophage polarization, and CD8+ T-cell metabolic suppression

  • By

  • Juan Wang

  • Kang Wang

  • Zhenhong Hu

  • Xueting Hu

  • May 25, 2026

  • 0 min

Share

  • 1

    HHLA2 is a novel immune checkpoint enriched in EGFR-mutant lung cancer, linking oncogenic signaling with immune regulation.

  • 2

    HHLA2 enhances tumor progression by promoting EGFR signaling and IL-10-dependent macrophage M2 polarization.

  • 3

    The HHLA2–KIR3DL3 axis suppresses CD8+ T-cell glutamine metabolism, representing a metabolic immune checkpoint.

  • 4

    Lower HHLA2 expression correlates with better responses to immunotherapy and increased tissue-resident memory T-cell infiltration.

  • 5

    Targeting the HHLA2–KIR3DL3 axis alongside EGFR tyrosine kinase inhibitors may enhance treatment for EGFR-mutant lung cancer.

Original Source(s)

HHLA2 as an emerging immune checkpoint in lung cancer: linking EGFR signaling, macrophage polarization, and CD8+ T-cell metabolic suppression

  • by Juan Wang, Kang Wang, Zhenhong Hu, Xueting Hu

  • May 25, 2026

Related Content

Case report: Helical tomotherapy-based whole lung irradiation with simultaneous integrated boost for pulmonary metastatic Ewing’s sarcoma: a case series report and feasibility analysis

Tumor irradiation promotes antigen dressing of dendritic cells to enhance CAR T cell persistence and efficacy in lung metastases

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer